Skip to main content

Summary

for people ages 18–80 (full criteria)
healthy people welcome
at San Francisco, California
study started
estimated completion:

Description

Summary

This is a pilot randomized controlled trial intervention to improve lifestyle behaviors (physical activity and health diet) for Filipino Americans with type 2 diabetes on metformin. If the PilAm Go4Health intervention demonstrates potential efficacy, it may identify effective intervention strategies to significantly reduce risks for heart disease risks (i.e., metabolic syndrome) in Filipino Americans.

Official Title

Pilipino Americans Go4Health Weight Loss Program to Prevent Heart Disease

Details

Filipino Americans are the second largest Asian population and fastest growing racial group in the United States. They have one of the highest rates of insulin resistance (type 2 diabetes = T2DM) and central obesity (fat distributions primarily in the abdominal region). T2DM and central obesity are two of five major risk factors for metabolic syndrome that lead to cardiovascular disease and stroke. Key factors contributing to obesity and T2DM in Filipinos are their physical inactivity, and a diet high in fat and soda intake. However, there are very few research studies on improving health behaviors to reduce risks for metabolic syndrome in Filipino Americans. To help reduce the risk of developing metabolic syndrome in overweight/obese Filipino Americans with T2DM, the proposed project will test a culturally appropriate health behavior intervention program to reduce weight and waist circumference, blood glucose levels (evaluating insulin resistance) through increasing physical activity, and lowering fat and sugar sweetened beverage intake. This intervention uses a mobile phone health app and social networking to encourage adherence to target health behaviors. The goals are to:

  1. To assess feasibility and acceptability of the culturally appropriate PilAm Go4Health Weight Loss Program
  2. To obtain preliminary estimates of the effect of the intervention on weight, BMI, and insulin resistance
  3. To conduct post-program process evaluations too improve the intervention relevancy for the target population.

Keywords

Insulin Resistance, Metabolic Syndrome Type 2 Diabetes cardiovascular disease prevention lifestyle intervention physical activity weight loss nutrition Filipinos culturally appropriate Diabetes Mellitus, Type 2 Heart Diseases Metabolic Syndrome X Insulin Resistance

Eligibility

You can join if…

Open to people ages 18–80

  1. Self-identified as Filipino
  2. Age > 18 years
  3. BMI for Asians > 23 kg/m2
  4. Physician diagnosed T2DM diabetes confirmed by clinical data (e.g. documentation of fasting blood glucose >126 mg/dL or a positive oral glucose tolerance test (OGTT) >200 mg/dl, HbA1c > 6.5%)
  5. On metformin for T2DM

4) waist circumference: men > 40 inches, women > 35 inches 6) Physically inactive - most leisure time spent without much physical activity 7) No cognitive impairment per the Mini-Cog test 8) has a mobile smartphone (iPhone 4s or above, or android phone) 9) English speaking. Only one member per household allowed to enroll in the study.

You CAN'T join if...

  1. Uncontrolled T2DM
  2. Glucose metabolism associated disease (Cushing's syndrome, Acromegaly, and Pheochromocytoma currently under treatment, chronic pancreatitis), 2) Thyroid disease
  3. sub-optimally treated
  4. Known medical conditions or other physical problems needing a special exercise program(e.g., prior myocardial infarction, history of angioplasty or angina, admission for hospital evaluation of chest pain, use of nitroglycerin for angina, chronic obstructive pulmonary disease, or uncontrolled hypertension)
  5. Recent acute coronary syndrome or revascularization, congested heart failure
  6. Currently participating in a lifestyle modification program
  7. Planning a trip outside of the US during the 6-month study period
  8. Known eating disorder
  9. Planning a surgery in the next 7-months
  10. Taking long-term antibiotics (including HIV-related agents), anti-tuberculosis agents(except INH alone as prophylaxis), or prescription weight-loss drugs

Location

  • San Francisco / Daly City Communities
    San Francisco, California, 94115, United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT02290184
Lead Scientist
Melinda S Bender
Study Type
Interventional
Last Updated
May 2016